DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Cancer

• Publication date

  2017-10-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/ijc.30870PMID 28677116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

  2016cited by this paper
• Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

  2016cited by this paper
• A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

  2016cited by this paper
• Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

  2016cited by this paper
• Mechanisms of Resistance to Antibody–Drug Conjugates

  2016cited by this paper
• DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

  2016influential reference
• Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation

  2016cited by this paper
• Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

  2015cited by this paper
• The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

  2015cited by this paper
• HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

  2015cited by this paper
• Trastuzumab emtansine: mechanisms of action and drug resistance

  2014cited by this paper
• Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

  2014cited by this paper
• HER2 aberrations in cancer: implications for therapy.

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

  2011cited by this paper
• Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• 223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance

  2010cited by this paper
• Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

  2009cited by this paper
• HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

  2008cited by this paper
• Assessment of a HER2 scoring system for gastric cancer: results from a validation study

  2008cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

  2004cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice

  1998cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• DX‐8951F, a water‐soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN‐38‐resistant variant

  1997cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

  year unknowncited by this paper

• Site-Specific Glycan Conjugation Improves Stability and Efficacy of an Antibody-Drug Conjugates Bearing DXd as a Cytotoxic Payload.

  2026cites this paper
• Significant efficacy of trastuzumab emtansine in HER2-positive relapsed mammary Paget’s disease: a case report and literature review

  2026cites this paper
• Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.

  2026cites this paper
• Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison.

  2026cites this paper
• Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.

  2026cites this paper
• An Engineered Fc with a Single Glycosylation Site Enables the Precise Conjugation of an Antibody with One Payload.

  2026cites this paper
• Valine-Alanine-Based Peptidomimetic Linker for Antibody-Drug Conjugates.

  2026cites this paper
• ABCG2-Mediated SN-38 Efflux Drives Resistance to Sacituzumab Govitecan in Urothelial Carcinoma.

  2026cites this paper
• Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates.

  2026cites this paper
• Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review

  2026cites this paper
• Mechanisms of resistance to antibody-drug conjugates in breast cancer.

  2026cites this paper
• Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer.

  2025cites this paper
• Mechanistic Investigation of Resistance to SHR-A1811 and T-DXd, the Third Generation of HER2-ADC, in Breast Cancer

  2025cites this paper
• In-situ dual-lighting system for HER2 nucleic acid and protein co-localization through simultaneous visual signal amplification in single pathological sections

  2025cites this paper
• Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition

  2025cites this paper
• Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions

  2025cites this paper
• Antibody-Drug Conjugates in Oncology: A Spotlight on Overcoming Resistance.

  2025cites this paper
• Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies

  2025cites this paper
• Targeting autophagy to enhance Nectin-4-MMAE efficacy in gastric cancer.

  2025cites this paper
• BC-Predict Database: A Curated Resource of Experimentally Validated Markers in Multidrug Resistance in Breast Cancer

  2025influential citation
• PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study

  2025cites this paper
• Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

  2025cites this paper
• Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer.

  2025cites this paper
• Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

  2025cites this paper
• Tyramide signal amplification-based detection system: A novel approach to improve detection efficiency for circulating tumor cells.

  2025cites this paper
• Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms.

  2025cites this paper
• Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy.

  2025cites this paper
• PBPK-PD Model for Predicting Pharmacokinetics, Tumor Growth Inhibition, and Toxicity Risks of Topoisomerase Inhibitor ADCs in Mice and Humans.

  2025cites this paper
• Strategy for the development of targeted agents for therapy of HER2-positive breast cancer

  2025cites this paper
• Antibody-drug conjugates in breast cancer: current resistance mechanisms and future combination strategies

  2025cites this paper
• Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions.

  2025cites this paper
• Improving the Therapeutic Selectivity of Trastuzumab Deruxtecan Using 8C2 Fab Fragments

  2025cites this paper
• Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes

  2025influential citation
• Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis

  2025cites this paper
• Current progress and remaining challenges of peptide–drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)?

  2025cites this paper
• Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates

  2025cites this paper
• CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance

  2025cites this paper
• TOP-1 Priority: Advancing Biomarker-Driven Patient Selection for the use of ADCs.

  2025cites this paper
• The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy

  2025cites this paper
• Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives

  2025cites this paper
• Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials.

  2025cites this paper
• Development of a Novel DNA Mono-alkylator Platform for Antibody Drug Conjugates.

  2024cites this paper
• Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy

  2024cites this paper
• Resistance to antibody–drug conjugates: A review

  2024cites this paper
• Tissue Biomarkers in Gastric Cancer Treatment: Present and Future

  2024cites this paper
• Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects

  2024cites this paper
• Construction of a prognostic model based on cuproptosis-related patterns for predicting survival, immune infiltration, and immunotherapy efficacy in breast cancer: Cuproptosis-based prognostic modeling in breast cancer

  2024cites this paper
• Synthesis and evaluation of homocamptothecin antibody-drug conjugates for cancer treatment.

  2024cites this paper
• Clinical strategies with antibody-drug conjugates as potential modifications for virotherapy.

  2024cites this paper
• Antibody-drug conjugates (ADCs): a novel therapy for triple-negative breast cancer (TNBC).

  2024cites this paper
• Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

  2024cites this paper
• Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

  2024cites this paper
• Exploring treatment options in cancer: tumor treatment strategies

  2024cites this paper
• Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?

  2024cites this paper
• Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies

  2024cites this paper
• Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance

  2024cites this paper
• Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development

  2024cites this paper
• HER-2 positive gastric cancer: Current targeted treatments.

  2024cites this paper
• Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates.

  2024cites this paper
• Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer

  2024cites this paper
• Antibody drug conjugates in the clinic

  2024cites this paper
• Antibody-drug conjugates: Principles and opportunities.

  2024cites this paper
• Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.

  2024cites this paper
• Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression

  2024cites this paper
• Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models

  2024cites this paper
• Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

  2024cites this paper
• Challenges and future of HER2-positive gastric cancer therapy

  2023cites this paper
• Payload diversification: a key step in the development of antibody–drug conjugates

  2023cites this paper
• Mechanisms of Resistance to Antibody–Drug Conjugates

  2023influential citation
• Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)

  2023cites this paper
• Antibody-drug conjugates: the clinical development in gastric cancer

  2023cites this paper
• Mechanisms of Resistance to Antibody-Drug Conjugates

  2023cites this paper
• Antibody–drug conjugates come of age in oncology

  2023cites this paper
• T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer

  2023cites this paper
• Can You Establish the Cause of This Patient's Shortness of Breath?

  2023cites this paper
• Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

  2023cites this paper
• Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry

  2023influential citation
• Exploration of the antibody–drug conjugate clinical landscape

  2023cites this paper
• In Vivo Biorthogonal Antibody Click for Dual Targeting and Augmented Efficacy in Cancer Treatment

  2023cites this paper
• Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2

  2023cites this paper
• ADCdb: the database of antibody–drug conjugates

  2023cites this paper
• Antibody-drug conjugates in oncology: insights into Current challenges

  2023influential citation
• Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor

  2023cites this paper
• Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

  2023cites this paper
• Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

  2023cites this paper
• Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

  2023cites this paper
• Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond

  2023cites this paper
• Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.

  2022cites this paper
• Novel development strategies and challenges for anti-Her2 antibody-drug conjugates

  2022cites this paper
• Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer

  2022cites this paper
• Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

  2022cites this paper
• Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials

  2022cites this paper
• The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates

  2022cites this paper
• Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf)

  2022cites this paper
• Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors

  2022cites this paper
• Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

  2022cites this paper
• Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy

  2022cites this paper
• Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, is effective in pediatric solid tumors: A report by the Pediatric Preclinical Testing Consortium.

  2022cites this paper
• Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review.

  2022cites this paper
• Selection of Payloads for Antibody–Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study

  2022cites this paper